Table 1 Baseline characteristics of patients with FSGS and comparison of baseline characteristics between patients with and without FSGS recurrence

Sex (M/F)

51/43

16/12

35/31

0.82

Age at onset (yr)

26 (1–61)

19 (4–57)

26 (1–61)

0.63

Age at diagnosis (yr)^*

28 (2–62)

23 (5–57)

29 (2–62)

0.25

Serum albumin at diagnosis (g/l)

27 ± 11 (n=60)

20 ± 9 (n=20)

31 ± 10 (n= 40)

<0.01

24-hour protein exretion (g)

8.0 ± 7.3 (n=42)

11.7 ± 8.8 (n=15)

5.9 ± 5.5 (n=27)

0.01

eGFR at diagnosis^† (ml/min/1.73 m²)

81 ± 53 (n=63)

104 ± 50 (n=21)

69 ± 51 (n=42)

0.01

Cause of FSGS

Familial/geneticFSGS (group I)

18 (19%)

0

18

<0.01

Secondary FSGS (group II)

10 (11%)

0

10

Idiopathic FSGS (group III)

66 (70%)

28

38

Bilateral nephrectomy before transplantation

6

1

5

0.67

Interval onset to diagnosis^* (yr)

0.5 (0–31)

0.3 (0–6.9)

0.8 (0–31.0)

0.07

Interval diagnosis to ESRD (yr)

3.9 (0.1-32.4)

4.9 (0.1-16.8)

3.7 (0.1-32.4)

0.96

Interval ESRD to transplantation

1.4 (0–9.3)

1.2 (0–4.7)

1.4 (0–9.3)

0.53

Age at transplantation (yr)

37 (5–69)

32 (10–62)

38 (5–69)

0.17

Donor Source

Deceased

75

24

51

0.57

Living unrelated

7

1

6

Living related

12

3

9

Donor age (yr)

35.5 (0–68)

36.5 (5–64)

35.5 (0–68)

0.91

Number of HLA mismatches

2.0 ± 1.2

2.0 ± 1.2

2.0 ± 1.2

0.77

Initial immunosuppressive regimen

P + CsA

54

18

36

0.38

P + Aza

11

5

6

P + CsA + MMF

13

2

11

P + tacro + MMF

14

3

11

Dacl + tacro + MMF

2

0

2